SPR Therapeutics

SPR Therapeutics is a commercial-stage medical device innovator addressing the critical need for non-opioid chronic pain therapies through its proprietary peripheral nerve stimulation platform. The company's SPRINT® PNS System differentiates itself with a minimally invasive, temporary lead placement and a 60-day treatment regimen, aiming to provide lasting pain relief without permanent implants. Having secured FDA clearances for multiple pain indications, SPR is executing a commercial rollout in the U.S. while continuing to expand its clinical evidence and explore new applications. The company operates in a high-growth market driven by the opioid crisis and demand for effective, non-addictive pain management solutions.

Minimally invasive, temporary peripheral nerve stimulation (PNS) system featuring a percutaneous lead placement and a 60-day treatment regimen designed to provide lasting pain relief without a permanent implant.

SPR competes in the neuromodulation space against giants like Abbott, Boston Scientific, and Nevro, which market permanent spinal cord and peripheral nerve stimulators. It also competes with other pain management modalities, including nerve ablation devices (e.g., from Avanos, Halyard), pharmacological treatments, and other non-implantable stimulation devices. Its key competitive differentiation is the temporary, minimally invasive treatment paradigm.